About VanEck Bionic Engineering UCITS ETF Accum -A- USD

CYBO invests in stocks. The fund's major sectors are Health Technology, with 97.31% stocks, and Distribution Services, with 2.79% of the basket. The assets are mostly located in the North America region.

CYBO top holdings are Stryker Corporation and Edwards Lifesciences Corporation, occupying 10.35% and 10.33% of the portfolio correspondingly.

CYBO assets under management is ‪4.22 M‬ EUR. It's fallen 3.24% over the last month.

CYBO fund flows account for ‪−943.10 K‬ EUR (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.

No, CYBO doesn't pay dividends to its holders.

CYBO expense ratio is 0.55% meaning you'd have to pay 0.55% of your investment to help manage the fund.

CYBO follows the MVIS Global Bionic Healthcare ESG Index - Benchmark TR Net. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.

CYBO invests in stocks.

CYBO price has fallen by −3.15% over the last month, and its yearly performance shows a −11.86% decrease. See more dynamics on CYBO price chart.
NAV returns, another gauge of an ETF dynamics, have fallen by −1.13% over the last month, showed a −2.63% decrease in three-month performance and has decreased by −11.59% in a year.